Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.
PLoS One. 2012;7(12):e51339. doi: 10.1371/journal.pone.0051339. Epub 2012 Dec 7.
Immunological mechanisms are increasingly recognized in the progression of myelodysplastic syndrome (MDS). Early-stage MDS (E-MDS) is characterized by autoimmune-mediated myelosuppression whereas late-stage MDS (L-MDS) involves immune evasion, giving dysplastic cells growth potential to progress into acute myeloid leukemia. T-helper (Th) 22 is involved in the pathogenesis of inflammatory autoimmunity and tumorigenesis. The roles of Th22 cells in the pathophysiology of E-MDS and L-MDS remain unsettled.
We studied 37 MDS patients (E-MDS, n = 17; L-MDS, n = 20) and 20 healthy controls to characterize their peripheral blood (PB), as well as 25 MDS patients and 10 healthy controls to characterize their bone marrow(BM). The expression of Interleukin-22 (IL-22), IL-17 or interferon gamma (IFN-γ) was examined in E-MDS, L-MDS patients and controls by flow cytometry. The mRNA expression levels of RAR-related orphan receptor C (RORC), IL-6, tumor necrosis factor alpha (TNF-α) and IL-23 in peripheral blood mononuclear cells (PBMCs) were determined by real-time quantitative polymerase chain reaction. The levels of IL-22 and IL-17 both in PB and BM plasma were examined by enzyme-linked immunosorbent assay.
In E-MDS, peripheral Th17 cells were significantly elevated and correlated with peripheral Th22 cells compared with healthy controls and L-MDS. Significantly higher levels of peripheral Th22 expansion, mRNA expression of IL-6, TNF-α and lower level of RORC mRNA expression were observed in L-MDS compared with E-MDS. No statistical difference was found in IL-23 mRNA expression or plasma IL-22, IL-17 levels among E-MDS, L-MDS and controls.
Our data demonstrated that L-MDS cohort had increased frequencies of peripheral Th22 cells and higher mRNA expression levels of IL-6 and TNF-α, indicating that Th22 cells along with Th17 cells or not are involved in the dynamic immune responses of MDS.
免疫机制在骨髓增生异常综合征(MDS)的进展中越来越受到重视。早期 MDS(E-MDS)的特征是自身免疫介导的骨髓抑制,而晚期 MDS(L-MDS)则涉及免疫逃逸,使病态细胞获得生长潜能,进展为急性髓系白血病。辅助性 T 细胞 22(Th22)参与炎症性自身免疫和肿瘤发生的发病机制。Th22 细胞在 E-MDS 和 L-MDS 病理生理学中的作用仍未确定。
我们研究了 37 名 MDS 患者(E-MDS,n = 17;L-MDS,n = 20)和 20 名健康对照者的外周血(PB),以及 25 名 MDS 患者和 10 名健康对照者的骨髓(BM)。通过流式细胞术检测 E-MDS、L-MDS 患者和对照组的白细胞介素 22(IL-22)、IL-17 或干扰素 γ(IFN-γ)的表达。实时定量聚合酶链反应测定外周血单个核细胞(PBMCs)中 RAR 相关孤儿受体 C(RORC)、IL-6、肿瘤坏死因子 α(TNF-α)和 IL-23 的 mRNA 表达水平。通过酶联免疫吸附试验检测 PB 和 BM 血浆中 IL-22 和 IL-17 的水平。
与健康对照者和 L-MDS 相比,E-MDS 患者外周血 Th17 细胞明显升高,并与外周血 Th22 细胞相关。与 E-MDS 相比,L-MDS 患者外周血 Th22 细胞扩增、IL-6、TNF-αmRNA 表达水平显著升高,RORC mRNA 表达水平较低。E-MDS、L-MDS 和对照组之间,IL-23 mRNA 表达或血浆 IL-22、IL-17 水平无统计学差异。
我们的数据表明,L-MDS 组外周血 Th22 细胞频率增加,IL-6 和 TNF-αmRNA 表达水平升高,提示 Th22 细胞与 Th17 细胞一起或不一起参与 MDS 的动态免疫反应。